<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063981</url>
  </required_header>
  <id_info>
    <org_study_id>icsmaugeri</org_study_id>
    <nct_id>NCT05063981</nct_id>
  </id_info>
  <brief_title>Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP.</brief_title>
  <official_title>Biomarkers Evaluation and Effect of Mepolizumab on Lower and Upper Airways Inflammation in Severe Refractory Eosinophilic Asthma and Nasal Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituti Clinici Scientifici Maugeri SpA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituti Clinici Scientifici Maugeri SpA</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe or difficult-to-treat asthma represent a small amount of total asthmatic&#xD;
      patients, but weight on the national health system for the costs of disease management.&#xD;
      Chronic rhinosinusitis with nasal polyposis, which the Italian severe/uncontrolled asthma&#xD;
      registry reported with a prevalence of 30%, represents a comorbidity that significantly&#xD;
      impact lung function and asthma control in severe asthma. Recent evidence indicates that&#xD;
      there is a consistent heterogeneity regarding mucosal alterations present in subjects with&#xD;
      nasal polyposis involving different pathways: inflammatory cells, remodeling, T cell&#xD;
      activation, local IgE production, alteration induced by interactions between microorganisms&#xD;
      and epithelial cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasal, bronchial and systemic inflammation can differ among patients with severe refractory&#xD;
      eosinophilic asthma with or without CRSwNP. Treatment with Mepolizumab could modify nasal,&#xD;
      bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma&#xD;
      and nasal polyposis acting on disease control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary function tests</measure>
    <time_frame>2 years</time_frame>
    <description>by the helium dilution method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal cytology</measure>
    <time_frame>2 years</time_frame>
    <description>mediator evaluations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced sputum</measure>
    <time_frame>2 years</time_frame>
    <description>high sensitive tests ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exhaled NO</measure>
    <time_frame>2 years</time_frame>
    <description>measurement of FeNO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>2 years</time_frame>
    <description>ELISA test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EBC sampling</measure>
    <time_frame>2 years</time_frame>
    <description>Î±-amylase activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NMR-based metabolomics</measure>
    <time_frame>2 years</time_frame>
    <description>NMR spectroscopy</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Asthma</condition>
  <condition>Nasal Polyps</condition>
  <condition>Sinusitis Chronic</condition>
  <arm_group>
    <arm_group_label>CRSwNP</arm_group_label>
    <description>10 patients with severe refractory eosinophilic asthma plus CRSwNP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No CRSwNP</arm_group_label>
    <description>10 patients with severe refractory eosinophilic asthma and no CRSwNP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control</description>
    <arm_group_label>CRSwNP</arm_group_label>
    <arm_group_label>No CRSwNP</arm_group_label>
    <other_name>Nucala</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll 10 patients with severe refractory eosinophilic asthma plus CRSwNP and 10&#xD;
        patients with severe refractory eosinophilic asthma and no CRSwNP, for whom treatment with&#xD;
        mepolizumab is indicated, according to the AIFA recommendations.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:age &gt;18 years&#xD;
&#xD;
          -  diagnosis of severe refractory asthma according to the ERS/ATS criteria ATS&#xD;
&#xD;
          -  Blood eosinophils &gt;150 cells/mcL at the screening visit and at least one value of 300&#xD;
             or more eosinophils/mcL during the previous year;&#xD;
&#xD;
          -  at least two exacerbations despite maximal therapy with long-acting bronchodilators&#xD;
             and high dose inhaled corticosteroids in the previous year or the need for continued&#xD;
             therapy with oral corticosteroids in addition to maximal inhaled therapy for at least&#xD;
             6 months in the previous year&#xD;
&#xD;
          -  written informed consent.&#xD;
&#xD;
          -  For CRSwNP diagnosis, the EPOS 2020 guidelines will be considered as reference. All&#xD;
             the above-mentioned inclusion criteria must be met.&#xD;
&#xD;
        Exclusion Criteria:Pregnancy&#xD;
&#xD;
          -  Eosinophilic Granulomatosis with Polyangiitis (EGPA);&#xD;
&#xD;
          -  Serious life threatening cardiopulmonary disorders;&#xD;
&#xD;
          -  Systemic immunologic disorder in the last 12 months;&#xD;
&#xD;
          -  Positive history for malignant tumors ever in patient's life;&#xD;
&#xD;
          -  Immunodeficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mauro Maniscalco, MD</last_name>
    <phone>+390824909350</phone>
    <email>mauro.maniscalco@icsmaugeri.it</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT05063981/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

